# Independent visual judge B — trust and persuasion

**Status:** preliminary visual audit of the rendered `editorial-r1` visitor journey. I inspected the live route at `http://15.204.83.60/CHL/PDP/editorial-r1/` at 390×844 and 1440×900 on 2026-09-12, plus the supplied final, v61 baseline, and category-comparable captures. This is not a conversion result or product-efficacy finding.

## Verdict

This is a substantial improvement over the v61 storefront in credibility, calm, and decision clarity. It looks like an intentionally authored supplement brand rather than a conventional white-label catalog. The strongest persuasion path is also the most defensible: a recognizable cognitive-lapse moment, a restrained active-folate explanation, an unusually legible full label, explicit high-dose caution, and a clear purchase choice. It still falls short of the strongest category trust systems because the social proof is visually present but not independently credible, creator proof is too thin to carry its position, and the scientific/provenance layer stops before answering the skeptical buyer's next question: “Why should I believe this company and this 15 mg dose?”

## Evidence-linked findings and causal diagnosis

1. **The hero leads with a real lived tension and makes the product relevant quickly.** The mobile first fold pairs “For the days you lose your train of thought” with a plain-language, qualified explanation of active 5-MTHF and a real bottle in a lived-in setting ([live 390 top capture](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/editorial-r1-rejection-audit-20260912/trust-captures/chl-trust-mobile-top.png); [final mobile top](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/fresh-design-20260912/qa/visual-final/mobile-390-top.png)). That pain → credible product bridge is more persuasive than v61's product-first hierarchy, where the buyer must parse a gallery and generic product heading before the fuller reasoning ([v61 mobile top](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/fresh-design-20260912/evidence/v61-baseline/mobile390-top.png)). **Evidence limit:** the blank hero-media region in that supplied v61 mobile capture is incomplete capture evidence, not a known baseline rendering defect; this comparison is limited to the visible hierarchy and copy.

2. **The offer feels unusually transparent for a subscription-first supplement page.** The full desktop purchase panel exposes first payment, shipping, renewal cadence, cancellation, one-time total, 60-day terms, and high-dose warning together ([final buy panel](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/fresh-design-20260912/qa/visual-final/desktop-1440-buy-topaligned.png)). This materially reduces the “free bottle” bait-and-switch risk. Cause: the financial terms are adjacent to choice and CTA rather than buried below, whereas competitors often begin with a more familiar catalog purchase path ([Seeking Health mobile](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/fresh-design-20260912/evidence/competitor-research/screenshots/seeking_health-mobile-top.png)).

3. **Ingredient transparency is the page's best earned-trust asset.** “Two ingredients. Nothing to hide.” is substantiated directly beside a readable Supplement Facts panel with dosage, other ingredients, disclaimer, and an “Open original” affordance ([final formula](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/fresh-design-20260912/qa/visual-final/desktop-1440-formula.png)). That turns a generic clean-label claim into inspectable evidence. It is more legible and editorially coherent than the v61 gallery-first above fold ([v61 desktop top](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/fresh-design-20260912/evidence/v61-baseline/desktop1440-top.png)).

4. **The product's safety posture is visible and human, but it also exposes the missing authority layer.** “15 mg … not right for everyone,” direction to consult a qualified healthcare professional, and an NIH fact-sheet link signal restraint rather than miracle marketing (live route text and [final buy panel](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/fresh-design-20260912/qa/visual-final/desktop-1440-buy-topaligned.png)). The causal gap is that the page says why to be cautious but does not yet make a source-backed case for CHL's formulation/dose choice in the visual journey. Needed makes testing and safety a named, navigable proof category; that is a stronger institutional pattern even though its treatment is more retail-like ([Needed mobile](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/fresh-design-20260912/evidence/competitor-research/screenshots/needed-mobile-top.png)).

5. **The routine image softens the medical feel, but it is correctly labelled as illustrative, so it cannot be mistaken for customer proof.** The woman-and-bottle scene supports the “daily habit” frame and the caption asks visitors to follow the product label and individual guidance ([live lower mobile](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/editorial-r1-rejection-audit-20260912/trust-captures/chl-trust-mobile-lower.png); [live lower desktop](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/editorial-r1-rejection-audit-20260912/trust-captures/chl-trust-desktop-lower.png)). This is a good trust choice. It also means the later creator-video cards must do the work of human validation; without readable creator identity, context, or actual playback inspection here, they presently read as an invitation to proof, not proof itself.

6. **The repeated “2,600 five-star reviews” signal is a trust liability until independently substantiated.** It is prominent in the hero and routine section ([final mobile top](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/fresh-design-20260912/qa/visual-final/mobile-390-top.png); [live lower desktop](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/editorial-r1-rejection-audit-20260912/trust-captures/chl-trust-desktop-lower.png)). The supplied count is operator-provided and was not independently audited, so it should be treated as unverified rather than a reason to trust. Do not fill the gap with legacy illustrative review quotations: they are unauthenticated and should not be reused.

7. **Relative to Ritual, the page is calmer and less interruption-prone; it needs Ritual/Needed-level proof architecture, not their surface style.** Ritual's product experience visibly advertises standards and a scientific advisory board, even though an email modal interrupts the journey ([Ritual mobile](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/fresh-design-20260912/evidence/competitor-research/screenshots/ritual-mobile-top.png); [Ritual middle](/home/ubuntu/Documents/WebBuildr/projects/clean-health-lab/research/fresh-design-20260912/evidence/competitor-research/screenshots/ritual-desktop-middle.png)). CHL's no-interruption editorial rhythm is stronger for a skeptical visitor; the missing improvement is accessible, source-backed formulation and manufacturing/quality provenance, not more badges or invented experts.

## Priorities if this proceeds to a revision

1. Put a concise, source-linked “why 15 mg / who should ask a clinician first / what we verify” proof module directly after the purchase decision or formula section, using only real available records.
2. Bind the five product/source-matched creator videos to clear, truthful creator context and watchable evidence; disclose the gifted relationship where applicable. Do not manufacture testimonials, clinician endorsements, laboratory tests, or review claims.
3. Keep the current offer disclosure, high-dose note, readable label, and illustrative-photo caption. Replace the unverified review-count prominence only when the underlying review evidence is independently verified.